Stay updated with breaking news from Adalimumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Specialists in rheumatology, dermatology and gastrointestinal disease discuss the evidence on efficacy and safety on switching patient to an adalimumab biosimilar. ....
There was a time not that long ago when Merck & Co. Inc.’s Keytruda (pembrolizumab), with its multiple cancer indications, was seen as the heir apparent to Humira’s title of the biggest blockbuster drug. Not anymore. That title now belongs to Novo Nordisk A/S’ semaglutide, approved as Ozempic in 2017 to treat diabetes and as Wegovy in 2021 to help with weight loss. ....